Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer.

Forse CL, Yilmaz YE, Pinnaduwage D, O'Malley FP, Mulligan AM, Bull SB, Andrulis IL.

Breast Cancer Res Treat. 2013 Feb;137(3):709-19. doi: 10.1007/s10549-012-2392-y. Epub 2013 Jan 4.

PMID:
23288345
2.

Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.

Larsson A, Fridberg M, Gaber A, Nodin B, Levéen P, Jönsson G, Uhlén M, Birgisson H, Jirström K.

BMC Cancer. 2012 Jul 8;12:282. doi: 10.1186/1471-2407-12-282.

3.

Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer.

Arnaout-Alkarain A, Kahn HJ, Narod SA, Sun PA, Marks AN.

Mod Pathol. 2007 Feb;20(2):183-91. Epub 2007 Jan 5.

4.

Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.

Li X, Cao X, Li X, Zhang W, Feng Y.

Cancer Sci. 2007 Oct;98(10):1592-6. Epub 2007 Jul 25.

5.

Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.

Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A.

Breast Cancer Res. 2001;3(3):183-91. Epub 2001 Feb 1.

6.

The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.

Voduc D, Nielsen TO, Cheang MC, Foulkes WD.

Hum Pathol. 2008 Oct;39(10):1431-7. doi: 10.1016/j.humpath.2008.03.004. Epub 2008 Jul 11.

PMID:
18620730
7.

Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients.

Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP.

J Am Coll Surg. 2000 Jul;191(1):1-6; discussion 6-8.

PMID:
10898177
8.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

9.

Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases.

Megha T, Neri A, Malagnino V, Caruso S, Onorati M, Roviello F, Tosi P.

Cancer Biol Ther. 2010 Feb;9(4):266-73. doi: 10.4161/cbt.9.4.10659. Epub 2009 Dec 22.

PMID:
20026902
10.

Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.

Takei H, Suemasu K, Kurosumi M, Horii Y, Ninomiya J, Yoshida M, Hagiwara Y, Inoue K, Tabei T.

Breast J. 2006 Sep-Oct;12(5 Suppl 2):S157-64.

PMID:
16958996
11.

[Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].

Zhang GH, Yang WT, Zhou XY, Zeng Y, Lu HF, Shi DR.

Zhonghua Yi Xue Za Zhi. 2007 Jan 16;87(3):155-60. Chinese.

PMID:
17425844
12.

ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer.

Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Kawaguchi M, Miura Y, Iwase H.

Clin Cancer Res. 2005 Jan 1;11(1):193-8.

13.

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31.

14.

The prognostic value of lymphatic and blood vessel invasion in operable breast cancer.

Lauria R, Perrone F, Carlomagno C, De Laurentiis M, Morabito A, Gallo C, Varriale E, Pettinato G, Panico L, Petrella G, et al.

Cancer. 1995 Nov 15;76(10):1772-8.

15.

Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients.

Tezuka K, Onoda N, Takashima T, Takagaki K, Ishikawa T, Wakasa T, Wakasa K, Hirakawa K.

Oncol Rep. 2007 May;17(5):997-1003.

PMID:
17390035
16.

The relationship between lymphatic vessell invasion, tumor size, and pathologic nodal status: can we predict who can avoid a third field in the absence of axillary dissection?

Wong JS, O'Neill A, Recht A, Schnitt SJ, Connolly JL, Silver B, Harris JR.

Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):133-7.

PMID:
10924982
17.

Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases.

Braun M, Flucke U, Debald M, Walgenbach-Bruenagel G, Walgenbach KJ, Höller T, Pölcher M, Wolfgarten M, Sauerwald A, Keyver-Paik M, Kühr M, Büttner R, Kuhn W.

Breast Cancer Res Treat. 2008 Dec;112(3):503-11. doi: 10.1007/s10549-007-9875-2. Epub 2007 Dec 29.

PMID:
18165897
18.

Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer.

Woo CS, Silberman H, Nakamura SK, Ye W, Sposto R, Colburn W, Waisman JR, Silverstein MJ.

Am J Surg. 2002 Oct;184(4):337-40.

PMID:
12383896
19.

Reduced expression of the breast cancer metastasis suppressor 1 mRNA is correlated with poor progress in breast cancer.

Zhang Z, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Iwase H.

Clin Cancer Res. 2006 Nov 1;12(21):6410-4.

20.

Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer.

Gurleyik G, Gurleyik E, Aker F, Aktekin A, Emir S, Gungor O, Saglam A.

Acta Chir Belg. 2007 Jun;107(3):284-7.

PMID:
17685254

Supplemental Content

Support Center